Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Go back to Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 228.69 +1.09 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $225.87 | 52 Week Low | $223.02 | |||
| Day High | $230.49 | P/E | 29.28 | |||
| Day Low | $225.51 | EPS | $7.81 | |||
| Volume | 1,332,341 | |||||
| (NASDAQ: BIIBV) | Delayed: 259.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $259.61 | 52 Week High | $ | |||
| Open | $0.00 | 52 Week Low | $ | |||
| Day High | $259.61 | P/E | N/A | |||
| Day Low | $259.61 | EPS | $ | |||
| Volume | 19,000 | |||||
